Chlamydia trachomatis is the most frequently detected sexually transmitted bacterial
pathogen in the world. Attempts to control these infections with screening programs and …

Urogenital Chlamydia serovars replicating in reproductive epithelium pose a unique
challenge to host immunity and vaccine development. Previous studies have shown that …

We evaluated the immunogenicity and efficacy of a candidate vaccine comprising the major
outer membrane protein (MOMP) multi-epitope of Chlamydia trachomatis. A short gene of …

Genomic analysis of the Chlamydiaceae has revealed a multigene family encoding large,
putatively autotransported polymorphic membrane proteins (Pmps) with nine members in …

Sexually transmitted Chlamydia trachomatis infections are a serious public-health problem.
With more than 90 million new cases occurring annually, C. trachomatis is the most common …

A monoclonal antibody (MAb), C10, that neutralized in vitro the infectivity of serovars C, I, J,
and L3 (members of the C and C-related complexes) of Chlamydia trachomatis was …

Monoclonal antibodies (MAbs) to the Chlamydia trachomatis mouse pneumonitis (MoPn)
major outer membrane protein (MOMP) were characterized for their ability to neutralize the …

Chlamydia trachomatis is the most prevalent sexually transmitted bacterial infection in the
world. In women, genital infection can cause endometritis and pelvic inflammatory disease …

Despite more than three decades of anti-chlamydial vaccine research and improved vaccine
strategies with new technologies, no vaccine candidate has protected against heterologous …

Chlamydia trachomatis sexually transmitted infections cause considerable morbidity and
socioeconomic burden worldwide, despite significant advances in our understanding of the …